Education only · provider review required
Retatrutide · Triple agonist in phase 3 trials
Not approved, not available — and heavily marketed anyway. Here is where it actually stands.
Medically reviewed by Bernard Garcia, MD
What it is
Retatrutide is an investigational peptide that activates three receptors: GLP-1, GIP and glucagon. It is in phase 3 clinical trials run by its manufacturer and is not approved anywhere. Phase 2 results published in 2023 showed large average weight reduction over 48 weeks, which is why it is widely discussed.
Anything sold online under this name is an unregulated copy of an unapproved investigational drug.
How it works
The glucagon-receptor component is intended to add energy-expenditure and liver-fat effects to the GLP-1/GIP appetite mechanisms. Phase 3 trials are measuring weight, cardiovascular outcomes and safety over longer periods; results and any approval decision are pending.
Research status
| Research area | Status |
|---|---|
| Chronic weight management | Phase 3 trials ongoing · not approved |
| Type 2 diabetes | Phase 3 trials ongoing |
| Long-term safety | Not established |
| Regulatory status (US FDA) | Investigational · no approval |
Status reflects published research context only and is not a statement of safety, efficacy, or suitability for any person.
Is it legal?
Retatrutide is an investigational drug with no approval in any country. It cannot be lawfully prescribed or compounded, and "research use only" products are not for human use. This is a general note, not legal advice.
Frequently asked questions
When will retatrutide be approved?
No date exists. Phase 3 results and regulatory review come first; this page will be updated when the status changes.
Can a provider prescribe it now?
No. It is investigational and not available outside clinical trials.
What about online sellers offering it?
Those products are unapproved, untested copies. They are the kind of product our safety page describes as a red flag.
Next step
Next step: a 3-minute confidential intake, reviewed by a licensed provider. No treatment is promised or implied.
Free · about 10 minutes · reviewed by a licensed physician
General education · Not medical advice · Provider approval required